How should intramuscular tranexamic acid be administered immediately, step‑by‑step, to an adult road‑traffic accident victim with active bleeding?

Intramuscular Tranexamic Acid Administration in Road Traffic Accident Victims: Step-by-Step Protocol

For immediate hemorrhage control in road traffic accident victims, administer tranexamic acid 1 gram (1000 mg) intramuscularly as two separate 5 mL injections (500 mg each) into different large muscle groups within 3 hours of injury, followed by hospital-based intravenous continuation. 1, 2

Critical Timing Window

• Administer within 3 hours of injury—efficacy decreases by 10% for every 15-minute delay, and administration after 3 hours may paradoxically increase bleeding death risk (RR 1.44). 3, 4, 2
• Maximum benefit occurs within the first 2 hours, with 32% reduction in bleeding deaths when given within 1 hour and 21% reduction between 1-3 hours. 4, 2
• Document the exact time of injury and time of TXA administration to ensure proper hospital follow-up and avoid duplicate dosing. 2

Patient Selection Criteria

Administer IM tranexamic acid to patients with:

• Active bleeding or clinical signs of hemorrhagic shock (systolic BP < 90 mmHg, tachycardia, altered mental status, pale/cool skin). 3, 2
• Suspected significant internal bleeding from torso trauma, pelvic fractures, or multiple injuries. 3, 5
• Time from injury ≤ 3 hours. 3, 4, 2

Do NOT administer if:

• More than 3 hours have elapsed since injury. 3, 4, 2
• Patient has known active intravascular clotting or DIC. 6, 7
• Patient has severe hypersensitivity to tranexamic acid. 6

Step-by-Step Administration Protocol

Step 1: Prepare Equipment

• Two 10 mL vials of tranexamic acid 100 mg/mL (1000 mg total). 6
• Two 5 mL syringes with intramuscular needles (21-23 gauge, 1.5 inch). 1
• Alcohol swabs for skin preparation. 1

Step 2: Calculate and Draw Dose

• Standard dose: 1 gram (1000 mg) total, divided as two 5 mL (500 mg) injections. 1, 2
• Draw 5 mL from each vial into separate syringes. 1
• Label syringes clearly to avoid confusion with other medications. 6

Step 3: Select Injection Sites

• Use two different large muscle groups to optimize absorption:
  • Preferred sites: Vastus lateralis (lateral thigh) and deltoid (upper arm), OR two separate vastus lateralis sites (opposite thighs). 1, 8
  • Alternative: Ventrogluteal muscles if patient positioning allows. 1
• Dividing the dose between two sites does not affect drug uptake but may reduce local reactions. 8

Step 4: Administer Injections

• Clean injection sites with alcohol swabs. 1
• Insert needle at 90-degree angle into muscle. 1
• Aspirate briefly to ensure no vascular penetration. 1
• Inject slowly over 30-60 seconds per site to minimize discomfort and local reactions. 1
• Withdraw needle and apply gentle pressure. 1

Step 5: Monitor and Document

• Monitor injection sites for mild reactions (pain, swelling, redness)—these are expected and well-tolerated. 1
• Document administration time, dose, and injection sites in patient care record. 2
• Communicate TXA administration to receiving hospital to ensure proper continuation therapy and avoid duplicate dosing. 2

Step 6: Arrange Hospital Transfer

• Therapeutic serum concentrations (5-10 mg/L) are reached within 4-11 minutes after IM injection and remain above therapeutic levels for 5.6-10 hours. 1
• Hospital must continue with second 1 gram dose intravenously over 8 hours to complete the evidence-based regimen. 3, 9, 2

Alternative Dosing for Severe Shock

If patient shows profound hemorrhagic shock (systolic BP < 70 mmHg, GCS < 9), consider 2 gram IM dose (four 5 mL injections across four different sites) to achieve serum concentrations comparable to IV administration more rapidly. 8, 2

• This higher dose (30 mg/kg for average 70 kg patient) provides serum levels equal to IV administration with minimal delay. 8

Critical Safety Considerations

Renal Impairment

• If known severe renal impairment exists, reduce dose as tranexamic acid is renally excreted and accumulates, causing neurotoxicity (seizures, altered mental status). 7, 6
• For creatinine clearance 10-50 mL/min: reduce to 10 mg/kg twice daily. 6
• For creatinine clearance < 10 mL/min: reduce to 10 mg/kg once daily. 6

Route-Specific Warnings

• NEVER administer intrathecally—this causes severe neurotoxicity and seizures. 6, 9
• FOR INTRAMUSCULAR USE ONLY in pre-hospital setting—do not attempt intravenous administration if not trained or equipped. 6, 1

Contraindications to Verify

• Do not give if patient has history of spontaneous coronary artery dissection (SCAD) due to MI risk. 7
• Avoid in patients with known active thrombosis, though large-scale trauma evidence shows no increased thromboembolic risk with appropriate use. 7, 2

Common Pitfalls to Avoid

• Do not delay administration waiting for IV access—IM route is specifically designed for pre-hospital use when IV access is difficult or time-consuming. 1, 5
• Do not use single injection site for full 1 gram dose—dividing between two sites optimizes absorption and reduces local reactions. 1, 8
• Do not administer if > 3 hours post-injury—this increases bleeding death risk rather than reducing it. 3, 4, 2
• Do not fail to communicate administration to hospital—duplicate dosing or missed continuation therapy compromises outcomes. 2
• Do not use standard dose in known severe renal failure—this causes drug accumulation and seizures. 7, 6

Expected Clinical Response

• Therapeutic plasma levels achieved within 4 minutes, with peak absorption at approximately 2 hours. 1
• Bioavailability of IM route is 77% compared to IV administration. 1
• Hemostatic effect maintained for 5.6-10 hours after single 1 gram IM dose. 1
• Mild injection site reactions (pain, erythema) occur but are well-tolerated and do not require treatment. 1